Vector Science files first quarterly results, targets August 2026 peptide revenue

The newly public company said VectorMist is advancing toward an FDA (U.S. drug regulator) 510(k) filing while peptide output is expected to scale to about 800,000 vials a month by early fall.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.